Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?

This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.

Authors

Publication Details

Journal
JAMA
Published
2026-10-16
DOI
https://doi.org/10.1001/jama.2026.20002
Primary Topic
Lipoproteins and Cardiovascular Health
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?

Jennifer Abbasi
JAMA
Lipoproteins and Cardiovascular Health
article

Lp(a)-Reducing Agent Pelacarsen Misses the Mark in Phase 3—Now What?

Jennifer Abbasi
article en

Abstract

This Medical News article discusses the top-line results from the Lp(a)HORIZON trial, which investigated lipoprotein(a) lowering to reduce major adverse cardiovascular events.

JAMA
Good health and well-being
Openalex Percentile: Top 10%
Lipoproteins and Cardiovascular Health
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.